About Us

Cognition Therapeutics, Inc.

Cognition Therapeutics, Inc. is a clinical stage neuroscience company developing drugs that help restore normal cellular damage responses in neurodegenerative and neuro-ophthalmic disorders. The company’s candidates work by binding to protein components of the σ-2 (sigma-2) receptor complex, which is present on synapses and acts as a key regulator of cellular damage and stress response. Receptor component proteins (PGRMC1 and TMEM97) control autophagy, cholesterol synthesis and lipid membrane-bound protein trafficking, all of which are associated with age-related CNS disorders.
Cognition’s lead candidate, CT1812, is an orally delivered, first-in-class, brain-penetrant small molecule drug designed to bind selectively to the σ-2 receptor complex. By so doing, the aim is to restore the damaged cellular processes that drive diseases such as Alzheimer’s disease, dry age-related macular degeneration (dry AMD), geographic atrophy and other conditions. The first indication the company is pursuing is mild-to-moderate Alzheimer’s disease. In this indication, seven clinical trials have been or are being conducted with CT1812 including a planned Phase 2 study anticipated to commence in 2021 in collaboration with the Alzheimer’s Clinical Trial Consortium (ACTC). These studies have been funded in large part by $117.6M in cumulative grants awarded by the National Institute on Aging, part of the NIH.

History

Cognition Therapeutics was founded on a unique combination of biological expertise in synaptic function and plasticity, a deep understanding of and focus on the role of toxic soluble proteins, and proprietary CNS-biased chemistry. Supported by dedicated investors as well as Alzheimer’s disease focused entities including the Alzheimer’s Drug Discovery Foundation and the National Institute on Aging of the NIH, Cognition’s founders, Susan Catalano, Ph.D. and Gilbert Rishton, Ph.D. and their team identified CT1812 and brought this molecule into Phase 2 clinical development.

Mission

Cognition’s mission is to stop the unrelenting progression of neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease and dementia with Lewy bodies (DLB), and by doing so alter the impact of the societal tsunami of these fatal diseases.

Pipeline

Based on its initial clinical trial in individuals with mild-to-moderate Alzheimer’s disease, CT1812 was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). CT1812 is covered by composition of matter patents worldwide.

CT1812 is currently in Phase 2 development for the treatment of mild-to-moderate Alzheimer’s disease. Cognition intends to expand its pipeline to indications beyond Alzheimer’s disease including dry AMD. More information about the company’s programs may be found here.

Biotechnology: Saving Lives & Transforming Healthcare in the 21st Century

Cognition Therapeutics is a member of the Biotechnology Innovation Organization (BIO), which is dedicated to promoting the value of the current and future biopharmaceutical industry. Modern biotechnology may be a young industry, but in just a few decades the entrepreneurs, scientists, researchers and investors working in this field will have established themselves at the forefront of medical innovation. To learn more about how their work may transform the way we treat patients with a wide range of once-devastating diseases, such as Alzheimer’s disease, and what tools, resources and policies will pave the way to these advances, please click here.